Over the past 7 days, the U.S. market has dropped 1.5%, yet it has risen by 13% over the last year, with earnings forecasted to grow by 18% annually. For investors willing to explore beyond well-known names, penny stocks—often associated with smaller or newer companies—can offer intriguing possibilities. Despite being a somewhat outdated term, penny stocks remain relevant for those seeking affordability and growth potential in today's market landscape.
Let's review some notable picks from our screened stocks.
Nautilus Biotechnology (NAUT)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating platform technology to quantify and unlock the complexity of the proteome in the United States, with a market cap of $122.51 million.
Operations: Currently, there are no reported revenue segments for this development stage life sciences company.
Market Cap: $122.51M
Nautilus Biotechnology, with a market cap of US$122.51 million, remains pre-revenue with only US$190K reported in revenue and no significant revenue streams. Despite being unprofitable, the company has maintained its financial stability by remaining debt-free for five years and having sufficient cash runway for over a year. Recent developments include the filing of a US$300 million shelf registration and advancements in their Iterative Mapping technology, which offers promising insights into disease mechanisms through proteoform analysis. However, the stock's high volatility may pose risks to investors seeking stable returns from penny stocks.
- Dive into the specifics of Nautilus Biotechnology here with our thorough balance sheet health report.
- Assess Nautilus Biotechnology's future earnings estimates with our detailed growth reports.
Seer (SEER)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Seer, Inc. is a life sciences company that develops and commercializes products aimed at decoding the proteome to enhance human health across several regions including the United States, China, Australia, Europe, Israel, Japan, and South Africa with a market cap of $105.76 million.
Operations: The company generates revenue from its Biotechnology (Startups) segment, amounting to $14.22 million.
Market Cap: $105.76M
Seer, Inc., with a market cap of US$105.76 million, is navigating significant executive changes and strategic challenges. The company reported US$14.22 million in revenue from its Biotechnology segment but remains unprofitable with a negative return on equity of -30.12%. Despite this, Seer has no debt and possesses sufficient cash runway for over three years based on current free cash flow trends. Recent boardroom dynamics include an unsolicited acquisition proposal reflecting market interest in its valuation, though internal governance issues raise concerns about strategic direction and shareholder confidence amidst ongoing activist investor pressures.
- Click here to discover the nuances of Seer with our detailed analytical financial health report.
- Understand Seer's earnings outlook by examining our growth report.
Viomi Technology (VIOT)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Viomi Technology Co., Ltd, through its subsidiaries, develops and sells home water solution products in the People's Republic of China with a market cap of $90.88 million.
Operations: The company generates revenue from online retailers, amounting to CN¥1.69 billion.
Market Cap: $90.88M
Viomi Technology faces challenges typical of penny stocks, including high volatility and recent delisting concerns from Nasdaq due to its share price falling below US$1. The company reported a significant decline in revenue to CN¥740 million for the first half of 2026, compared to CN¥1.48 billion the previous year, alongside a net loss of CN¥26.29 million. Despite having more cash than debt and covering its short-term liabilities with assets, Viomi remains unprofitable with negative return on equity. Recent strategic moves include a US$100 million shelf registration and completing a share buyback program valued at US$3.8 million.
- Jump into the full analysis health report here for a deeper understanding of Viomi Technology.
- Examine Viomi Technology's earnings growth report to understand how analysts expect it to perform.
Key Takeaways
- Click through to start exploring the rest of the 324 US Penny Stocks now.
- Seeking Other Investments? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com